Alector Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Alector, Inc. (Nasdaq: ALEC) announced on December 6, 2022, that it granted stock options and restricted stock units (RSUs) to eight new employees.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Alector, Inc. (Nasdaq: ALEC) announced on December 6, 2022, that it granted stock options and restricted stock units (RSUs) to eight new employees. The awards included options to purchase 91,851 shares of common stock at an exercise price of $9.27 per share and RSUs for 40,961 shares. These grants are part of Alector’s 2022 Inducement Equity Incentive Plan. The stock options will vest over four years, while the RSUs will vest over three years.
Positive
- New employee stock options and RSUs may attract talent.
- Stock options and RSUs granted under an established incentive plan.
Negative
- None.
Details
News Market Reaction – ALEC
The recorded move for ALEC in the trading session of this news was -0.58%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology and innate immuno-oncology, today announced that on December 6, 2022, the compensation committee of Alector’s board of directors granted 8 (eight) new employees options to purchase an aggregate of 91,851 shares of the company’s common stock and restricted stock units (RSUs) for an aggregate of 40,961 shares of the company’s common stock. These awards are made under Alector’s 2022 Inducement Equity Incentive Plan (the “Plan”).
The stock options each have an exercise price of
The above-described awards were each granted as an inducement material to the employees entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan.
About Alector
Alector is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases, and innate immuno-oncology. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector has discovered and is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable rejuvenated immune cells to counteract emerging brain pathologies. Alector’s immuno-neurology product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease. This scientific approach is also the basis for the company’s immuno-oncology programs. Alector is headquartered in South San Francisco, California. For additional information, please visit www.alector.com.
Alector Contacts:
1AB (media)
Dan Budwick
973-271-6085
dan@1abmedia.com
Argot Partners (investors)
Carrie McKim
Argot Partners
212.600.1902
alector@argotpartners.com
Source: Alector, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.